Increased serum matrix metalloproteinase 9 levels in systemic lupus erythematosus patients with neuropsychiatric manifestations and brain magnetic resonance imaging abnormalities.

OBJECTIVE To evaluate whether serum matrix metalloproteinase 9 (MMP-9) levels are associated with neuropsychiatric manifestations, particularly cognitive dysfunction, as evaluated by neuropsychological testing and brain magnetic resonance imaging (MRI) abnormalities in patients with systemic lupus erythematosus (SLE). METHODS MMP-9 determinations were made in 44 patients with SLE and 43 healthy controls who underwent a clinical neurologic and neuropsychological investigation in order to identify neuropsychiatric manifestations. Cerebral MRI scans with volumetric estimation of intracranial cerebrospinal fluid spaces, T1-weighted lesions, and T2-weighted lesions were performed for all subjects. SLE activity was assessed by the European Consensus Lupus Activity Measure (ECLAM) index, and accumulated neuropsychiatric abnormality was assessed by the Systemic Lupus International Collaborating Clinics (SLICC)/American College of Rheumatology damage index. RESULTS No significant difference was found in serum MMP-9 levels between the overall group of SLE patients and controls. However, SLE patients who had at least 1 neuropsychiatric manifestation (NPSLE patients) had significantly higher serum MMP-9 concentrations than did SLE patients without neuropsychiatric syndromes (P = 0.009). Among patients with NPSLE, those with cognitive deficits had significantly higher concentrations of serum MMP-9 than did those with normal cognitive function (P = 0.027). Furthermore, serum MMP-9 levels had a significant positive correlation with the volumes of T1-weighted and T2-weighted lesions in the brain MRI (P = 0.031 and P = 0.015, respectively). The concentration of serum MMP-9 correlated significantly with the SLICC index but not with the ECLAM index. CONCLUSION Elevated levels of serum MMP-9 in patients with SLE may reflect neuropsychiatric involvement, particularly cognitive dysfunction. The serum MMP-9 concentration may be associated with small- vessel cerebral vasculopathy and increased risk of cerebral ischemic events in patients with SLE.

[1]  J. Malmivuo,et al.  Semi-automatic tool for segmentation and volumetric analysis of medical images , 1998, Medical and Biological Engineering and Computing.

[2]  J. Arenillas,et al.  Matrix Metalloproteinase-9 Pretreatment Level Predicts Intracranial Hemorrhagic Complications After Thrombolysis in Human Stroke , 2003, Circulation.

[3]  F. Jennekens,et al.  The central nervous system in systemic lupus erythematosus. Part 2. Pathogenetic mechanisms of clinical syndromes: a literature investigation. , 2002, Rheumatology.

[4]  G. Gronseth,et al.  Neuropsychiatric syndromes in lupus: Prevalence using standardized definitions , 2002, Neurology.

[5]  E. Mozes,et al.  Activity of matrix metalloproteinase‐9 is elevated in sera of patients with systemic lupus erythematosus , 2002, Clinical and experimental immunology.

[6]  P. H. N. Oomen,et al.  Growth hormone replacement does not elevate albuminuria in GH-deficient adults , 2002, Scandinavian journal of clinical and laboratory investigation.

[7]  T. Lehtimäki,et al.  Serum matrix metalloproteinase-9 concentration in angiographically assessed coronary artery disease , 2002, Scandinavian journal of clinical and laboratory investigation.

[8]  A. Kalela.  Factors affecting serum matrix metalloproteinase-9 with special reference to atherosclerosis , 2002 .

[9]  J. Arenillas,et al.  Matrix Metalloproteinase Expression Is Related to Hemorrhagic Transformation After Cardioembolic Stroke , 2001, Stroke.

[10]  A. Auvinen,et al.  Validity of the new American College of Rheumatology criteria for neuropsychiatric lupus syndromes: a population-based evaluation. , 2001, Arthritis and rheumatism.

[11]  J. Peltola,et al.  The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus , 2001, Neurology.

[12]  J. Arenillas,et al.  Matrix Metalloproteinase Expression After Human Cardioembolic Stroke: Temporal Profile and Relation to Neurological Impairment , 2001, Stroke.

[13]  H. Lijnen.  Plasmin and Matrix Metalloproteinases in Vascular Remodeling , 2001, Thrombosis and Haemostasis.

[14]  M. Esiri,et al.  White Matter Damage Is Associated With Matrix Metalloproteinases in Vascular Dementia , 2001, Stroke.

[15]  Sillanaukee,et al.  Association of serum sialic acid and MMP‐9 with lipids and inflammatory markers , 2000, European journal of clinical investigation.

[16]  T. Sharshar,et al.  Matrix metalloproteinase-9 is increased and correlates with severity in Guillain-Barré syndrome , 1999, Neurology.

[17]  W. Brooks,et al.  Neuroimaging in neuropsychiatric systemic lupus erythematosus. , 1999, Arthritis and rheumatism.

[18]  D. Gladman,et al.  The SLICC/ACR damage index: progress report and experience in the field , 1999, Lupus.

[19]  L. Matrisian,et al.  Measurement of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Blood and Tissues: Clinical and Experimental Applications , 1999, Annals of the New York Academy of Sciences.

[20]  P. Dastidar,et al.  Volumes of brain atrophy and plaques correlated with neurological disability in secondary progressive multiple sclerosis , 1999, Journal of the Neurological Sciences.

[21]  Caroline Gordon,et al.  The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. , 1999, Arthritis and rheumatism.

[22]  M. Cuzner,et al.  Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system , 1999, Journal of Neuroimmunology.

[23]  J. Palace,et al.  Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study. , 1999, Brain : a journal of neurology.

[24]  R. Ross,et al.  Atherosclerosis is an inflammatory disease. , 1998, American heart journal.

[25]  P. Birembaut,et al.  Increased serum stromelysin-1 levels in systemic lupus erythematosus: lack of correlation with disease activity. , 1999, The Journal of rheumatology.

[26]  T. Ueno,et al.  Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. , 1998, Journal of the American College of Cardiology.

[27]  K. Obata,et al.  Increased levels of matrix metalloproteinase-3 in sera from patients with active lupus nephritis. , 1998, Clinical and experimental rheumatology.

[28]  R. Hughes,et al.  Matrix metalloproteinase expression during experimental autoimmune neuritis. , 1998, Brain : a journal of neurology.

[29]  P Dastidar,et al.  Applicability of semi-automatic segmentation for volumetric analysis of brain lesions. , 1998, Journal of medical engineering & technology.

[30]  S. Kusachi,et al.  Time dependent alterations of serum matrix metalloproteinase-1 and metalloproteinase-1 tissue inhibitor after successful reperfusion of acute myocardial infarction. , 1997, Heart.

[31]  J. Fisk,et al.  Cognitive function in systemic lupus erythematosus: results of a 5-year prospective study. , 1997, Arthritis and rheumatism.

[32]  M. Weiner,et al.  MRI‐MRS of the Brain in Systemic Lupus Erythematosus , 1997, Annals of the New York Academy of Sciences.

[33]  S. West,et al.  Analysis of cognitive and psychological deficits in systemic lupus erythematosus patients without overt central nervous system disease. , 1996, Arthritis and rheumatism.

[34]  T. Nikkari,et al.  Macrophages contain 92-kd gelatinase (MMP-9) at the site of degenerated internal elastic lamina in temporal arteritis. , 1996, The American journal of pathology.

[35]  A. Koch,et al.  Expression of matrix metalloproteinase 9 (96-kd gelatinase B) in human rheumatoid arthritis. , 1996, Arthritis and rheumatism.

[36]  E. Goetzl,et al.  Matrix metalloproteinases in immunity. , 1996, Journal of immunology.

[37]  Y. Soini,et al.  72 KD and 92 KD type IV collagenase, type IV collagen, and laminin mRNAs in breast cancer: a study by in situ hybridization. , 1994, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[38]  D. Gladman,et al.  Dilemmas in neuropsychiatric lupus. , 1993, Rheumatic diseases clinics of North America.

[39]  G. Opdenakker,et al.  Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders , 1992, Journal of Neuroimmunology.

[40]  M. Liang,et al.  A controlled study of the prevalence of cognitive dysfunction in randomly selected patients with systemic lupus erythematosus. , 1992, Arthritis and rheumatism.

[41]  E. Hay,et al.  Psychiatric disorder and cognitive impairment in systemic lupus erythematosus. , 1992, Arthritis and rheumatism.

[42]  J. Fisk,et al.  Cognitive impairment in patients with systemic lupus erythematosus. , 1992, The Journal of rheumatology.

[43]  J. Denburg,et al.  Prevalence of Cognitive Impairment in Systemic Lupus Erythematosus , 1986, The Journal of nervous and mental disease.

[44]  J F Fries,et al.  The 1982 revised criteria for the classification of systemic lupus erythematosus. , 1982, Arthritis and rheumatism.

[45]  A. Claudy,et al.  Disease activity in systemic lupus erythematosus , 1979, Clinical and experimental dermatology.